PureTech Health (NASDAQ:PRTC) Shares Gap Down – What’s Next?

Shares of PureTech Health plc (NASDAQ:PRTC) gapped down prior to trading on Tuesday . The stock had previously closed at $22.15, but opened at $21.00. PureTech Health shares last traded at $21.00, with a volume of 600 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Leerink Partners initiated coverage on shares of PureTech Health in a report on Monday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a report on Monday, September 9th.

PureTech Health Trading Down 3.4 %

The company’s 50-day moving average is $21.26 and its two-hundred day moving average is $22.41.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC purchased a new position in shares of PureTech Health plc (NASDAQ:PRTC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.